Trial Profile
One-arm, Phase II, Single-center Clinical Study of Anlotinib in the Treatment of Recurrent Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 15 Dec 2020 Status changed from recruiting to completed.
- 17 Nov 2018 New trial record